12:00 AM
 | 
Dec 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tasigna nilotinib: Additional Phase III data

Additional data from the open-label, international Phase III ENESTnd trial in 846 patients showed that twice-daily 300 and 400 mg Tasigna produced significantly higher MMR rates at 24 months vs. once-daily 400 mg Gleevec imatinib (71% and 67%, respectively, vs. 44%). CCyR rates also were significantly higher for low- and...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >